

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number  
**WO 2004/017947 A1**

(51) International Patent Classification<sup>7</sup>: A61K 9/16, 9/20

(74) Agent: BOWMAN, Paul, Alan; Lloyd Wise, 1- 19 New  
Oxford Street, London WC1A 1LW (GB).

(21) International Application Number:

PCT/GB2003/003654

(22) International Filing Date: 20 August 2003 (20.08.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0219516.2

21 August 2002 (21.08.2002)

GB

0219744.0

23 August 2002 (23.08.2002)

GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): PHOQUS  
PHARMACEUTICALS LIMITED [GB/GB]; 10 Kings  
Hill Avenue, Kings Hill, West Malling, Kent ME19 4PQ  
(GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): TIAN, Wei  
[GB/GB]; 6 Sawyers Close, Minety, Malesbury, SN16  
9QS (GB). LANGRIDGE, John [GB/GB]; 3 Green  
Avenue, Astley, Manchester, M29 7EH (GB).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

WO 2004/017947 A1

(54) Title: USE OF AN AQUEOUS SOLUTION OF CITRIC ACID AND A WATER-SOLUBLE SUGAR LIKE LACTITOL AS  
GRANULATION LIQUID IN THE MANUFACTURE OF TABLETS

(57) Abstract: The use of an aqueous solution of citric acid and a highly water-soluble sugar as a binder for the granulation of tablet  
excipients.

USE OF AN AQUEOUS SOLUTION OF CITRIC ACID AND A WATER-SOLUBLE SUGAR LIKE LACTITOL AS GRANULATION LIQUID IN THE MANUFACTURE OF TABLETS

The present invention relates to tablet compositions and methods of making tablets. In particular the invention relates to the use of a water-soluble sugar as a lubricant/anti-adherent during the tablet compression process of tablet compositions containing citric acid.

Citric acid (2-hydroxy-1,2,3-propanetricarboxylic acid), in either monohydrate or anhydrous form, is widely used in pharmaceutical formulations and food products as an acidifying agent, an antioxidant, a buffering agent, a chelating agent or a flavour enhancer. Citric acid monohydrate loses water of crystallisation in dry air or when heated to about 40°C. It is slightly deliquescent in moist air. Citric acid is frequently incorporated into effervescent tablets, chewable tablets and fast disintegrating tablets.

Fast disintegrating tablets for oral administration are known. These tablets are readily disintegratable in the mouth, can be taken without water and without chewing.

WO 99/47126 discloses a physiologically acceptable tablet comprising a compressed tablet formulation free of organic solvent residue that rapidly disintegrates when placed in a body cavity, comprising at least one water-soluble non-saccharide polymer, the tablet has a hardness factor of between 0.5 kiloponds and 12.0 kiloponds.

US 5576014 discloses intrabucally dissolving compressed mouldings comprising a saccharide having low mouldability having been granulated with a saccharide having high mouldability. The mouldings exhibit quick disintegration and dissolution in the buccal cavity and have an adequate hardness.

US 6024981 discloses a hard, compressed, rapidly dissolvable dosage form adapted for direct oral dosing comprising an active ingredient and a matrix including a non-direct compression filler and a lubricant, the dosage form being adapted to rapidly dissolve in the mouth of a patient and thereby liberate the active ingredient.

US-A-4886669 discloses a water-dispersible tablet comprising:

- a) microparticles which contain at least one pharmaceutically active substance
- b) at least one disintegrant and
- c) a swellable material which is able to generate a high viscosity when coming into contact with water and which is selected from guar gum, xanthan gum, alginates, dextran, pectins, polysaccharides, sodium or calcium carboxymethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose,

which tablet disintegrates rapidly in water forming a homogeneous suspension of high viscosity that can easily be swallowed.

WO99/44580 discloses a formulation for preparing a fast disintegrating tablet comprising a drug in multiparticulate form, one or more water insoluble excipients, one or more disintegrants; and optionally one or more substantially water-soluble excipients, the amount of the ingredients being such as to provide a disintegration time for the tablet in the mouth in the order of seventy five seconds or less. It is stated superior tablet properties can be achieved by choosing appropriate amounts of the ingredients according to the classification shown below:

- a) insoluble ingredient: this includes the amount of drug either coated or uncoated and the amount of insoluble excipients including the insoluble inorganic salts used as filler diluents (e.g. di- or tri-basic calcium phosphate), organic filler (e.g. microcrystalline cellulose) or water insoluble lubricant (e.g. magnesium stearate, sodium steary fumarate, stearic acid or glyceryl behenate) and glidant (e.g. talc, silicone dioxide etc.).
- b) substantially soluble components e.g. the amount of compression sugars (e.g. lactose), flavouring agents, sweeteners, binders and surfactants etc.
- c) disintegrant, especially super-disintegrant, such as, maize starch or modified starches, cross-linked polyvinylpyrrolidone or sodium carboxymethylcellulose.

For constant ratios of ingredients a) and b) increasing the amount of disintegrant generally gives poorer friability values and increased disintegration times. In view of this the amount of super disintegrant c) should

not be excessive and is therefore preferably in the range 0.5 to 30%, most preferably 1 to 20%, most preferably 2 to 15% by weight of tablet.

British Patent Application No. 0204771.0 discloses a fast disintegrating tablet comprising an active ingredient and one or more disintegrants characterised in that disintegrant or a combination of disintegrants is present in the form of agglomerates having an average agglomerated particle size of at least 50 microns, said agglomerates comprising at least 10% by weight of disintegrant.

EP 0454396 discloses a pharmaceutical tablet composition for active compounds in free base form having one or more undesirable tableting properties comprising:

a premixture consisting essentially of from about 85 to about 99.9 percent by weight of said premixtures of said active compound and from about 0.1 to about 15 percent of said premixtures of citric acid; and,  
one or more additional formulation ingredients.

Effervescence is defined as the evolution of bubble of gas from a liquid, as the result of a chemical reaction. Effervescent mixtures have been known and used medicinally for many years. The effervescent tablets can be either dissolved in water to provide a carbonated or sparkling liquid drink for ingestion or directly placed in the oral cavity where the effervescence facilitates tablet disintegration. Citric acid and sodium bicarbonate are the most commonly used effervescent agents, as disclosed for example, in WO95/23594, WO00/38657 and US 6071539.

Chewable tablets are often desired for its convenience and patient acceptance (e.g. for young children and some geriatric patients who can not swallow tablet easily) and for rapid onset of bioactivity (such as obtained from a chewable antacid or anthelmintic tablet) (Darueala, J.B. (1980) Chewable tablets, in Pharmaceutical dosage forms: tablets, Volume I, eds. Lieberman, H. A. and Lachman, L.).

Tablets are made by compressing a granular formulation on a tablet press. The tablet press typically has a set of tooling consisting of a die, an upper punch and a lower punch. Sheth, B.B., Bandelin F. J. and Shangraw R. F. (Compressed tablets, in Pharmaceutical dosage forms: tablets, Volume I, eds. Lieberman, H. A. and Lachman, L. (1980)) describe the compression process in several stages: the first stage is the filling cycle during which the lower punch is lowered to a preset point to form a cavity in the die to provide a volume corresponding to the correct fill weight for the tablet. Next the upper punch descends into the die to compress the tablet. Then the lower punch is raised flush with the surface of the die tablet so the tablet can be ejected.

Tablet presses operate at production rates up to a few thousand tablets a minute. Hence, a tablet formulation must first be prepared in a suitable form for compression on a tablet press. This process is referred as granulation. Wet granulation is often the preferred granulation process, which consists of the following basic unit operations:

1. Preparation of powder mixture with screening and mixing

2. Addition of binder solution and mixing with powder to appropriate wetness
3. Drying the solid-liquid blend
4. Milling the dry granulation to size
5. Addition of lubricant, glidant, and/or other excipients prior to compression

Generally it is important that effervescent tablets, or chewable tablets or fast disintegrating tablets have a pleasing taste, flavour and mouthfeel to ensure patient compliance. A key function of citric acid in these formulations is flavour enhancement. To attain a smooth flavour/taste sensation, it is preferable to have citric acid evenly distributed within the tablet matrix. One way of obtaining the even distribution of citric acid is to use it in an aqueous solution as the granulating liquid for the preparation of tablet granules. However, it has proved difficult to prepare tablets from such granules due to extensive sticking during compression.

Sticking refers to the adhesion on the punch faces and occurs when tablets do not leave the punch faces clean. The tablet faces become dull and/or pitted during compression, and the condition progressively worsens to the point where the tablets chip and break and are hard to remove from the lower punch or to pull apart from the upper. Lubricants or anti-adherents are added to the granulation mixture to resolve the problems of sticking.

The primary function of tablet lubricants is to reduce the friction arising at the interface of tablet and die wall during compression and ejection. The primary function of anti-adherents is to prevent sticking to the punch and to a lesser extent, the die wall. With many materials these functions are interchangeable and are difficult to separate completely. Common lubricants and anti-adherents are magnesium stearate, stearic acid, talc, calcium stearate, sodium stearate, sodium lauryl sulfate etc. Magnesium stearate is frequently the preferred lubricant/anti-adherent at an application level 0.25 to 2%.

The sticking problem associated with using citric acid solution as granulation liquid cannot be resolved with an increasing amount of conventional lubricants and anti-adherents.

It has been surprisingly found that this problem can be successfully resolved with the incorporation of a water-soluble sugar in the citric acid solution for granulation.

According to one aspect of the invention there is provided the use of an aqueous solution of citric acid and a highly water-soluble sugar as a binder for the granulation of tablet excipients.

According to a second aspect of the invention there is provided a composition for compressing into tablets comprising granules of tablet excipients in which the granules comprise citric acid and highly water-soluble sugar as binder.



According to a further aspect of the invention there is provided a tablet comprising granules of tablet excipient in which said granules comprise citric acid and highly water-soluble sugar as binder.

According to a further aspect of the invention there is provided a method of making a tablet comprising the steps of:

- (i) granulating tablet excipients using an aqueous solution of citric acid and a highly water-soluble sugar as a binder,
- (ii) drying the granules and optionally reducing the size of the dried granules,
- (iii) compressing said dried granules, optionally with additional tablet excipients in a tablet press to form a tablet, wherein the presence of said highly water-soluble sugar acts as a lubricant/anti-adherent in the tablet press.

Any suitable food grade or pharmaceutical grade citric acid can be used in the present invention. The citric acid can be present either in the monohydrate crystalline form or in the anhydrous form.

Highly water-soluble sugars are referred to those substances based on simple crystalline C5 or C6 sugar structures. The sugars can be mono-, di-, tri- and polysaccharides with the degree of polymerisation of less than 20. Preferably the degree of polymerisation is less than 10.

Examples of highly water-soluble sugars are glucose, sucrose, maltose, lactose, arabinose, xylose, ribose, fructose, mannose, galactose, sorbose,

trehalose, sorbitol, xylitol, mannitol, maltitol, lactitol, isomaltol, maltodextrin, hydrogenated starch hydrolysed products. The preferred sugars include maltitol, lactitol, sucrose, trehalose and mixtures thereof.

Preferably, the weight ratio of citric acid to the highly water-soluble sugar used in the aqueous solution is from 1:10 to 10:1; more preferably, 2:10 to 10:2; most preferably, from 5:10 to 10:5.

The citric acid is generally present in an amount of from 1 to 10% by weight based on the granules in which it is present.

The tablet excipients may be selected from a wide range of ingredients known in tablet compositions in the art. The precise selection which will depend upon the desired properties of tablet to be formed e.g. fast disintegrating, sustained release, effervescent, chewable etc. Non-limiting tablet excipients include binders, disintegrants, diluents, active ingredients e.g. drugs, antibiotics etc., flavouring, flow aids, surfactants etc.

The invention will be illustrated by the following Examples in which the following ingredients were used:

- |                      |  |
|----------------------|--|
| Mannitol SD200:      | mannitol having an average particle size of about 200 $\mu\text{m}$ manufactured by Roquette |
| Citric acid:         | manufactured by Tate & Lyle Ltd  |
| Polyplasdone® XL-10: | crospovidone having an average particle size of about 30 $\mu\text{m}$                       |

Mannitol:	mannitol having an average particle size of about 60µm
Explotab®:	sodium starch glycolate having an average particle size about 40 µm

Tablets were prepared using a Mannesty F3 press using normal 10 mm concave toolings. The toolings (upper punch, lower punch and die) were regularly examined for any signs of sticking during compression.

All parts and percentages are by weight unless otherwise stated.

#### Examples:

##### Example 1 (Comparative)

A fast disintegrating tablet was prepared by wet granulating mannitol (85.3 parts), sodium starch glycolate (Explotab) (5.0 parts) and aspartame (0.5 part) using a citric acid (5.0 part) solution. The wet granules were then dried in a forced air oven at 55°C to a moisture content of less than 1%. The dried granules were then screened through 1 mm sieve and combined with 4.0 parts of crospovidone (Polyplasdone XL-10), 0.1 part lemon flavour and 0.1 part orange flavour to give a total of 100 parts of granulation A.

Granulation A is then combined with lubricants for tabulating studies.

	B	C	D	E	F	G	H
Granulation A	95.0	92.0	94.0	93.0	95.0	97.0	89.0
Mg stearate	-	-	1.0	-	-	1.0	1.0
Talc	-	3.0	-	-	3.0	-	3.0
Na stearyl fumerate	-	-	-	2.0	2.0	2.0	2.0
Glycerol behenate	5.0	5.0	5.0	5.0	-	-	5.0
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0

There were evidences of sticking with all the lubricant systems used.

#### Example 2 (Comparative)

A fast disintegration tablet was prepared according to the formulation described below:

Formulation component	% w/w
Mannitol	90.7
Citric acid	2.3
Crospovidone	6.0
Magnesium stearate	1.0
Total	100.0

Citric acid was used to granulate mannitol. The granulation process was as described in Example 1. The dried granules were then combined with crospovidone and magnesium stearate for tableting studies.

There was evidence of sticking.

### Example 3 (Invention)

A fast disintegration tablet was prepared according to the formulation described below:

Formulation component	% w/w
Mannitol	88.4
Citric acid	2.3
Maltitol	2.3
Crospovidone	6.0
Magnesium stearate	1.0
Total	100.0

Citric acid/maltitol was used to granulate mannitol. The granulation process was as described in Example 1. The dried granules were then combined with crospovidone and magnesium stearate for tabulating studies.

There was no evidence of sticking.

**Example 4 (Invention)**

A fast disintegrating tablet was prepared incorporating two separate granule formulations:

Formulation component	Granulation A	Granulation B
Mannitol SD200	91.0	-
Mannitol M60	-	60.0
Explotab	4.0	-
Citric acid	2.5	7.5
Lactitol	2.5	7.5
Crospovidone	-	25.0
Total	100	100.0

Both granules were granulated with citric acid/lactitol solution. The granulation procedure was as described in Example 1. The tablet formulation used was as follows:

Formulation component	% w/w
Granule A	74.3
Granule B	24.0
Aspartame	0.5
Lemon flavour	0.2
Magnesium stearate	1.0
Total	100.0

The tablets were pressed to 1.8 kp, with a mean tablet weight of 248.7 mg, a mean thickness of 4.2 mm and a diameter of 10.1 mm. These tablets had a friability of 0.63% according to the standard USP friability method and an oral disintegration time of 15 seconds.

There was no evidence of sticking.

**Example 5 (Invention)**

Formulation of sildenafil tablet:

Formulation component	mg/tablet
Sildenafil granules	185.75
Agglomerated disintegrant granules	60.00
Aspartame	1.25
Lemon flavour	0.50
Magnesium stearate	2.50
Total	250.0

Sildenafil granules were prepared according to the following formulation:

Formulation component	%
Sildenafil citrate	37.81
Mannitol SD200	45.19
Vivastar (sodium starch glycolate)	7.00
Citric acid	5.00
Lactitol	5.00
Total	100.00

To prepare the sildenafil granule, citric acid and lactitol were dissolved in water. Sildenafil citrate, mannitol SD200 and sodium starch glycolate were blended in a food processor for 10 minutes, the citric acid/lactitol solution was added and mixed in, and the resulting wet granules were dried in a tray drier at 50°C.

Agglomerated disintegrant granules were prepared according to the following formulation:

Formulation component	%
Mannitol (M60)	60.00
Polyplasdone XL-10	25.00
Citric acid	7.50
Lactitol	7.50
Total	100.00



To prepare the agglomerated disintegrant granules, citric acid and lactitol were dissolved in deionised water, mannitol and polyplasdone were dry mixed for 10 minutes in a food mixer. The citric acid/lactitol solution was added to the dry mixture to form wet granules. The wet granules were dried in a forced air oven at 50°C to achieve a moisture level of less than 2%. The dried granules were screened and the 75 to 250 micron size range was obtained.

Tableting: the sildenafil granules and agglomerated disintegrant granules were placed in a suitable container. Aspartame and lemon flavour were screened, added to the mixture and blended for 10 minutes. Magnesium stearate was screened, added to the mixture and blended for a further 2 minutes. Tablets were prepared using a Stoke B2 rotary press fitted with 16 stations of 3/8 inch (9.525 mm) normal concave tooling. There was no evidence of sticking.

The tablets had an average weight of 252 mg and a mean crushing strength of 1.1 kp. The oral disintegration time was 28 seconds.

Example 6 (Invention)

Tablets incorporating concentrated sildenafil granules

Formulation of sildenafil tablet:

Formulation component	mg/tablet
Sildenafil granules	76.77
Mannitol granules	107.73
Agglomerated disintegrant granules	60.00
Aspartame	2.00
Lemon flavour	1.00
Magnesium stearate	2.50
Total	250.0

Sildenafil granules were prepared according to the following formulation:

Formulation component	%
Sildenafil citrate	91.50
Lemon flavour	1.00
Aspartame	2.50
Citric acid	2.50
Lactitol	2.50
Total	100.00

To prepare the sildenafil granule, citric acid and lactitol were dissolved in water. Sildenafil citrate, lemon flavour and aspartame were blended in a food processor for 10 minutes, the citric acid/lactitol solution was added and mixed in, and the resulting wet granules were dried in a tray drier at 50°C.

Mannitol granules were prepared according to the following formulation.

Formulation component	%
Mannitol (SD200)	91.00
Vivastar (sodium starch glycolate)	4.00
Citric acid	2.50
Lactitol	2.50
Total	100.00

To prepare the mannitol granules, citric acid and lactitol were dissolved in deionised water, mannitol and Vivastar were mixed for 10 minutes in a food mixer. The citric acid/lactitol solution was added to the dry mixture to form wet granules. The wet granules were dried in a forced air oven at 50°C to achieve a moisture level of less than 1%.

Agglomerated disintegrant granules were prepared according to Example 5.

Tableting: the sildenafil granules, mannitol granules, agglomerated disintegrant granules were placed in a suitable container. Aspartame and lemon flavour were screened, added to the mixture and blended for 10 minutes. Magnesium stearate was screened, added to the mixture and

blended for a further 2 minutes. Tablets were prepared using a Colton 204 rotary press fitted with 4 stations of 10mm normal concave tooling (chromed).

There was no evidence of sticking.

The tablets had an average weight of 252.5 mg and a mean crushing strength of 1.1 kp. The oral disintegration time was 12 seconds demonstrating the significant improvement in oral disintegration time when concentrated sildenafil granules were incorporated.

#### Example 7 (Invention)

Tablets incorporating concentrated sildenafil granules and an increased amount of sweetener

Formulation of sildenafil tablet:

Formulation component	mg/tablet
Sildenafil granules	90.00
Mannitol granules	95.00
Agglomerated disintegrant granules	60.00
Lemon flavour	2.50
Magnesium stearate	2.50
Total	250.0

Sildenafil granules were prepared according to the following formulation:

Formulation component	%
Sildenafil citrate	78.04
Acesulfame K (high intensity sweetener)	16.40
Citric acid	2.78
Lactitol	2.78
Total	100.00

To prepare the sildenafil granules, citric acid and lactitol were dissolved in water. Sildenafil citrate and acesulfame K were blended in a food processor for 10 minutes, the citric acid/lactitol solution was added and mixed in, and the resulting wet granules were dried in a tray drier at 50°C.

Mannitol granules were prepared according to Example 6.

Agglomerated disintegrant granules were prepared according to Example 5.

Tableting: the sildenafil granules, mannitol granules, agglomerated disintegrant granules were placed in a suitable container. Lemon flavour was screened, added to the mixture and blended for 10 minutes. Magnesium stearate was screened, added to the mixture and blended for a further 2 minutes. Tablets were prepared using a Colton 204 rotary press fitted with 4

stations of 10mm normal concave tooling (chromed). There was no evidence of sticking.

The tablets had an average weight of 251.1 mg and a mean crushing strength of 1.4 kp. The oral disintegration time was 15 seconds demonstrating the significant improvement in oral disintegration time when concentrated sildenafil granules were incorporated. The tablets had a strong bitter taste which lingered in the mouth for more than 5 minutes suggesting that the bitter taste can not be successfully masked by sweetener alone.

#### Example 8 (Invention)

Tablets incorporating concentrated sildenafil granules and a solubilisation inhibitor

Formulation of sildenafil tablet:

Formulation component	mg/tablet
Sildenafil granules	110.20
Mannitol granules	62.50
Agglomerated disintegrant granules	60.00
Lemon flavour	5.00
Acesulfame K	9.80
Magnesium stearate	2.50
Total	250.0

Sildenafil granules were prepared according to the following formulation:

Formulation component	%
Sildenafil citrate	60.50
Acesulfame K	8.30
Sodium carbonate	26.20
Citric acid	2.50
Lactitol	2.50
Total	100.00

To prepare the sildenafil granules, citric acid and lactitol were dissolved in distilled water. Sildenafil citrate, sodium carbonate and acesulfame K were blended in a food processor for 10 minutes, the citric acid/lactitol solution was added and mixed in, and the resulting wet granules were dried in a tray drier at 50°C.

Mannitol granules were prepared according to Example 6.

Agglomerated disintegrant granules were prepared according to Example 5.

Tableting: the sildenafil granules, mannitol granules, agglomerated disintegrant granules were placed in a suitable container. Acesulfame K and lemon flavour was screened, added to the mixture and blended for 10 minutes. Magnesium stearate was screened, added to the mixture and blended for a further 2 minutes. Tablets were prepared using a Colton 204

rotary press fitted with 4 stations of 10mm normal concave tooling (chromed).

There was no evidence of sticking.

The tablets had a pleasant sweet taste without the characteristic bitterness of sildenafil demonstrating the taste masking function of sodium carbonate. It was of interest to note that no effervescence was detected within the mouth,

#### Example 9 (Invention)

Tablets incorporating concentrated sildenafil granules and a solubilisation inhibitor.

Formulation of sildenafil tablet:

Formulation component	mg/tablet
Sildenafil granules	116.00
Mannitol granules	58.50
Agglomerated disintegrant granules	60.00
Lemon flavour	5.00
Acesulfame K	8.00
Magnesium stearate	2.50
Total	250.0



Sildenafil granules were prepared according to the following formulation:

Formulation component	%
Sildenafil citrate	63.70
Acesulfame K	8.71
Sodium carbonate	27.59
Total	100.00

To prepare the sildenafil granule, sildenafil citrate, sodium carbonate and acesulfame K were blended in a food processor for 10 minutes, distilled water was added and mixed in, and the resulting wet granules were dried in a tray drier at 50°C.

Mannitol granules were prepared according to Example 6.

Agglomerated disintegrant granules were prepared according to Example 5.

Tableting: the sildenafil granules, mannitol granules, agglomerated disintegrant granules were placed in a suitable container. Acesulfame K and lemon flavour was screened, added to the mixture and blended for 10 minutes. Magnesium stearate was screened, added to the mixture and blended for a further 2 minutes. Tablets were prepared using a Colton 204 rotary press fitted with 4 stations of 10mm normal concave tooling (chromed). There was no evidence of sticking.

The tablets had an average weight of 260.0 mg and a mean hardness of 0.9 kp. The oral disintegration time was 10 seconds demonstrating the significant improvement in oral disintegration time when concentrated sildenafil granules were incorporated. The tablets had a pleasant sweet taste without the characteristic bitterness of sildenafil demonstrating the taste masking function of sodium carbonate. No effervescence was detected within the oral cavity.

## CLAIMS

1. The use of an aqueous solution of citric acid and a highly water-soluble sugar as a binder for the granulation of tablet excipients.
2. The use as claimed in Claim 1 in which the highly water-soluble sugar is based on simple crystalline C5 or C6 sugar structures and is a mono-, di, tri or polysaccharide with a degree of polymerisation of less than 20, preferably less than 10.
3. The use as claimed in Claim 2 in which the highly water-soluble sugar is selected from glucose, sucrose, maltose, lactose, arabinose, xylose, ribose, fructose, mannose, galactose, sorbose, trehalose, sorbitol, xylitol, mannitol, maltitol, lactitol, isomaltol, maltodextrin, hydrogenated starch hydrolysed products and mixtures thereof.
4. The use as claimed in Claim 3 in which the sugar is selected from maltitol, lactitol, sucrose, trehalose and mixtures thereof.
5. The use as claimed in any preceding claim in which the weight ratio of citric acid to highly water-soluble sugar is from 1:10 to 10:1.
6. The use as claimed in Claim 5 in which the weight ratio of citric acid to highly water-soluble sugar is from 2:10 to 10:2, preferably 5:10 to 10:5.

7. The use as claimed in any preceding claim in which the citric acid is present in an amount of from 1 to 10% by weight based on the granules.
8. A composition for compressing into tablets comprising granules of tablet excipients in which the granules comprise citric acid and highly water-soluble sugar as binder.
9. A composition as claimed in Claim 8 in which the highly water-soluble sugar is based on simple crystalline C5 or C6 sugar structures and is a mono, di, tri or polysaccharide with a degree of polymerisation of less than 20, preferably less than 10.
10. A composition as claimed in Claim 9 in which the highly water-soluble sugar is selected from glucose, sucrose, maltose, lactose, arabinose, xylose, ribose, fructose, mannose, galactose, sorbose, trehalose, sorbitol, xylitol, mannitol, maltitol, lactitol, isomaltol, maltodextrin, hydrogenated starch hydrolysed products and mixtures thereof.
11. A composition as claimed in Claim 10 in which the sugar is selected from maltitol, lactitol, sucrose, trehalose and mixtures thereof.
12. A composition as claimed in any one of Claims 8 to 11 in which the weight ratio of citric acid to highly water-soluble sugar is from 1:10 to 10:1.

13. A composition as claimed in Claim 12 in which the weight ratio of citric acid to highly water-soluble sugar is from 2:10 to 10:2, preferably 5:10 to 10:5.
14. A composition as claimed in any one of Claims 8 to 13 in which the citric acid is present in an amount of from 1 to 10% by weight based on the granules.
15. A tablet comprising granules of tablet excipient in which said granules comprise citric acid and highly water-soluble sugar as binder.
16. A tablet as claimed in Claim 15 in which the highly water-soluble sugar is based on simple crystalline C5 or C6 sugar structures and is a mono-, di, tri- or polysaccharide with a degree of polymerisation of less than 20, preferably less than 10.
17. A tablet as claimed in Claim 16 in which the highly water-soluble sugar is selected from glucose, sucrose, maltose, lactose, arabinose, xylose, ribose, fructose, mannose, galactose, sorbose, trehalose, sorbitol, xylitol, mannitol, maltitol, lactitol, isomaltol, maltodextrin, hydrogenated starch hydrolysed products and mixtures thereof.
18. A tablet as claimed in Claim 17 in which the sugar is selected from maltitol, lactitol, sucrose, trehalose and mixtures thereof.

19. A tablet as claimed in any one of Claims 15 to 18 in which the weight ratio of citric acid to highly water-soluble sugar is from 1:10 to 10:1.
20. A tablet as claimed in Claim 19 in which the weight ratio of citric acid to highly water-soluble sugar is from 2:10 to 10:2, preferably 5:10 to 10:5.
21. A tablet as claimed in any one of Claims 15 to 20 in which the citric acid is present in an amount of from 1 to 10% by weight based on the granules.
22. A method of making a tablet comprising the steps of:
- (i) granulating tablet excipients using an aqueous solution of citric acid and a highly water-soluble sugar as a binder,
  - (ii) drying the granules and optionally reducing the size of the dried granules,
  - (iii) compressing said dried granules, optionally with additional tablet excipients in a tablet press to form a tablet, wherein the presence of said highly water-soluble sugar acts as a lubricant/anti-adherent in the tablet press.
23. A method of making a tablet as claimed in Claim 22 in which the highly water-soluble sugar is based on simple crystalline C5 or C6 sugar structures and is a mono-, di, tri or polysaccharide with a degree of polymerisation of less than 20, preferably less than 10.

24. A method of making a tablet as claimed in Claim 23 in which the highly water-soluble sugar is selected from glucose, sucrose, maltose, lactose, arabinose, xylose, ribose, fructose, mannose, galactose, sorbose, trehalose, sorbitol, xylitol, mannitol, maltitol, lactitol, isomaltol, maltodextrin, hydrogenated starch hydrolysed products and mixtures thereof.

25. A method of making a tablet as claimed in Claim 24 in which the sugar is selected from maltitol, lactitol, sucrose, trehalose and mixtures thereof.

26. A method of making a tablet as claimed in Claims 22 to 25 in which the weight ratio of citric acid to highly water-soluble sugar is from 1:10 to 10:1.

27. A method of making a tablet as claimed in Claim 26 in which the weight ratio of citric acid to highly water-soluble sugar is from 2:10 to 10:2, preferably 5:10 to 10:5.

28. A method of making a tablet as claimed in Claims 22 to 27 in which the citric acid is present in an amount of from 1 to 10% by weight based on the granules.

# INTERNATIONAL SEARCH REPORT

Int      nel Application No  
P... \_B 03/03654

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7    A61K9/16    A61K9/20		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7    A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 1 116 485 A (GERGELY GERHARD) 18 July 2001 (2001-07-18) example 1	1-4
E	WO 03 072084 A (LANGRIDGE JOHN ;LEIGHTON ANN (GB); PHOQUS LTD (GB); TIAN WEI (GB)) 4 September 2003 (2003-09-04) examples 8,9	1-28
<input type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the International filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the International filing date but later than the priority date claimed "T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the International search  21 November 2003		Date of mailing of the International search report  04/12/2003
Name and mailing address of the ISA European Patent Office, P.B. 6818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  Sindel, U



# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Patent Application No

PCT/GB 03/03654

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 1116485	A	18-07-2001	AU 3368701 A 24-07-2001
		CA 2396223 A1 19-07-2001	
		CN 1394136 T 29-01-2003	
		WO 0151026 A2 19-07-2001	
		EP 1116485 A2 18-07-2001	
		JP 2003519649 T 24-06-2003	
		NO 20022875 A 06-08-2002	
		US 2002168386 A1 14-11-2002	
WO 03072084	A	04-09-2003	WO 03072084 A1 04-09-2003